Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Isis Pharmaceuticals, Merck, Galapagos, Inpharmatica, Invitrogen, Sentigen

Isis Pharmaceuticals, Merck, Galapagos, Inpharmatica, Invitrogen, Sentigen

Dec 07, 2006
Premium
Isis Receives $1M Milestone From Merck
 
Isis Pharmaceuticals said this week that it has received a $1 million milestone payment from Merck based on the initiation of clinical development of a compound discovered through a joint research collaboration.
 
Details about the clinical candidate were not disclosed.
 
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Letter Urges New Inquiry

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

Great Apes Get Shots, Too

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Woodcock on Vaccines, More

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

Science Paper Examines Molecular Contributors to Kidney Fibrosis

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.

Mar
09
Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
24
Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

Apr
21
Featured Webinar

Single-cell Multiomics Analysis of Clonal Evolution in Myeloid Malignancies

Sponsored by
Mission Bio

This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies. 

What's Popular?

In Gene Silencing/Gene Editing

  1. ERS Genomics Licenses CRISPR Patents to Otsuka Pharmaceutical

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.